"NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results (Q38723957)

5 September 2017

1 reference

title

"NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results (English)

1 reference

5 September 2017

Archana Thakur

1

1 reference

PubMed ID

26848610

5 September 2017

Lawrence G Lum

series ordinal

2

1 reference

PubMed ID

26848610

5 September 2017

language of work or name

English

0 references

publication date

5 February 2016

1 reference

Expert Opinion on Biological Therapy

5 September 2017

1 reference

5 September 2017

16

1 reference

5 September 2017

5

1 reference

5 September 2017

675-688

1 reference

Therapeutic antibodies for autoimmunity and inflammation

5 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Dual targeting strategies with bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

High interstitial fluid pressure - an obstacle in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Myeloid-derived suppressor cells in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Immunity, Inflammation, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Improved endpoints for cancer immunotherapy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Blinatumomab: a historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Bispecific T-cell engaging antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Targeting T cells to tumor cells using bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

RECRUIT-TandAbs: harnessing the immune system to kill cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

An evolutionarily conserved program of B-cell development and activation in zebrafish

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Designing heterodimeric two-stranded alpha-helical coiled-coils. Effects of hydrophobicity and alpha-helical propensity on protein folding, stability, and specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Antibody therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Potent immunomodulatory effects of the trifunctional antibody catumaxomab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Two new trifunctional antibodies for the therapy of human malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Chronic renoprotective effect of pulsatile perfusion machine RM3 and IGL-1 solution in a preclinical kidney transplantation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Potential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Hybrid antibodies can target sites for attack by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

High expression of TROP2 correlates with poor prognosis in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Discovery of novel tumor markers of pancreatic cancer using global gene expression technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

TROP2 expression and its evolving role in tumor pathogenesis in systemic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

A new class of bispecific antibodies to redirect T cells for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

ImmTACs for targeted cancer therapy: Why, what, how, and which

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Characterization of a novel single-chain bispecific antibody for retargeting of T cells to tumor cells via the TCR co-receptor CD8

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Adoptive cellular therapy: a race to the finish line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Sequential affinity purification of peroxidase tagged bispecific anti-SARS-CoV antibodies on phenylboronic acid agarose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

TROP2 expression as prognostic marker for gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

Separation and Isolation of Fractions of Rabbit Gamma-Globulin containing the Antibody and Antigenic Combining Sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1150996

10.1517/14712598.2016.1150996

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference

PubMed ID

26848610